Cardiovascular Diseases Clinical Trial
— EXSTATICOfficial title:
The Effects of Supervised Exercise Training in the Primary Prevention of Cardiovascular Disease in Stain-Users and Non Statin-Users
Cardiovascular disease (CVD) refers to any condition that affects the heart and/or blood vessels (e.g. heart attack, stroke) and is the leading cause of death and disability worldwide. Regular exercise and statin therapy are widely recommended as frontline prevention strategies to reduce CVD risk. Recent changes to National Health Service (NHS) healthcare guidelines state that even individuals with a relatively low risk of CVD (≥10% risk score) should take a statin. When prescribed after a heart attack or stroke, both exercise and statins reduce the risk of a CVD-related death by ~25%, with some evidence to suggest that the combination of these therapies may offer additive cardiovascular protection. However, far less is known about the combined effects of exercise and statin therapy in primary CVD prevention (i.e. before a CVD event). Poor blood vessel function represents the earliest stage of CVD, which can be measured with ultrasound at different regions of the body (limbs, brain, heart) to sensitively detect early CVD risk. Regular exercise provides a variety of cardiovascular benefits and has a direct therapeutic effect on blood vessel function. In contrast, statin therapy primarily reduces CVD risk by lowering cholesterol, which may also improve blood vessel function. Although both therapies can separately reduce CVD risk, the interaction between exercise training and statin therapy on blood vessel function has never been directly compared in the setting of primary prevention, and it's currently unknown whether a combination of both therapies offers additional cardiovascular benefit. Therefore, the main aims of this study are to (i) investigate the effect of supervised exercise training on blood vessel function (limbs, brain, heart) in individuals with a CVD-risk score of ≥10% and (ii) examine whether these exercise effects differ in individuals taking a statin compared to those not taking a statin.
Status | Recruiting |
Enrollment | 80 |
Est. completion date | January 1, 2026 |
Est. primary completion date | January 1, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 50 Years to 65 Years |
Eligibility | Inclusion Criteria: Statin Users: - Sedentary - Non-smokers - 50-65 years old - A 10-year CVD-risk score > 10% (estimated via QRISK3) - Weight stable (<5% weight change over the last 3 months) - Prescription of an 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA) inhibitor (statin) in stable dose for a minimum of 3 months and maximum of 3 years Non-Statin Users: - Sedentary - Non-smokers - 50-65 years old - A 10-year CVD-risk score > 10% (estimated via QRISK3) - Weight stable (<5% weight change over the last 3 months) Exclusion Criteria (Statin Users and Non-Statin Users): - History or signs/symptoms of established cardiovascular, metabolic, renal or musculoskeletal disease - Diagnosed with familial hyperlipidaemia and/or diabetes mellitus - Stage 2 hypertension (=160/100 mmHg) - Any contraindications to exercise (e.g. unstable angina, severe orthopaedic conditions) and/or advised by GP not to undertake exercise - BMI >40kg/m2 - Current smoker or within 6 months of cessation - Use of any medication other than statins (e.g., fibrates, metformin, thiazolidinediones, orlistat, anti-hypertensives) that could independently alter lipid metabolism and/or vascular function - Post-menopausal female and using hormone replacement therapy, or pre-menopausal using oral contraceptives that independently alter lipid metabolism and/or vascular function |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Cardiff Metropolitan University | Cardiff |
Lead Sponsor | Collaborator |
---|---|
Cardiff Metropolitan University | Health and Care Research Wales |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in 7-day physical activity monitoring: Intensity of activity | Each participant will be issued with a small lightweight tri-axial accelerometer (activPAL Professional Physical Activity Monitor Technologies Ltd., Glasgow, UK), that will examine 7-day habitual physical activity levels. This device will be worn around the participant's waist continuously for seven consecutive days and will assess and monitor any physical activity and categorise activity bouts into light, moderate and vigorous intensity activity based on metabolic equivalent of task (METS)/hour/day. | Pre and post intervention (12 weeks) | |
Other | Change in 7-day physical activity monitoring: Frequency of activity | Each participant will be issued with a small lightweight tri-axial accelerometer (activPAL Professional Physical Activity Monitor Technologies Ltd., Glasgow, UK), that will examine 7-day habitual physical activity levels. This device will be worn around the participant's waist continuously for seven consecutive days and will assess the frequency of any activity bout (bouts/hour/day). | Pre and post intervention (12 weeks) | |
Other | Change in 7-day physical activity monitoring: Duration of activity | Each participant will be issued with a small lightweight tri-axial accelerometer (activPAL Professional Physical Activity Monitor Technologies Ltd., Glasgow, UK), that will examine 7-day habitual physical activity levels. This device will be worn around the participant's waist continuously for seven consecutive days and will assess the duration of any activity bout (mins per bout). | Pre and post intervention (12 weeks) | |
Other | Change in 7-day physical activity monitoring: Frequency of sedentary periods | Each participant will be issued with a small lightweight tri-axial accelerometer (activPAL Professional Physical Activity Monitor Technologies Ltd., Glasgow, UK), that will examine 7-day habitual physical activity levels. This device will be worn around the participant's waist continuously for seven consecutive days and will assess and monitor the frequency of any sedentary periods (bouts/hour/day) | Pre and post intervention (12 weeks) | |
Other | Change in 7-day physical activity monitoring: Duration of sedentary periods | Each participant will be issued with a small lightweight tri-axial accelerometer (activPAL Professional Physical Activity Monitor Technologies Ltd., Glasgow, UK), that will examine 7-day habitual physical activity levels. This device will be worn around the participant's waist continuously for seven consecutive days and will assess and monitor the duration of any sedentary periods (mins per bout) | Pre and post intervention (12 weeks) | |
Other | Change in 24-hour ambulatory blood pressure | participant will be issued with a wearable automated blood pressure monitoring device. This validated Mobil-O-Graph system (IEM Germany) will non-invasively measure 24-hour ambulatory blood pressure, aortic pressure and vascular haemodynamics. A small blood pressure cuff will be placed around the upper arm of the participant and connected to a halter monitor for 24 hours. Clear instructions on how to fit and position this device, as well as guidance on how long this device should be worn will be provided by a member of the research team | Pre and post intervention (12 weeks) | |
Other | Change in VO2peak cardiopulmonary max test | Participants will be required to complete a maximal exercise test (maximal oxygen consumption [VO2max] test) on a motorised treadmill . Initially, participants will be required to complete a 2 minute slow walking warm-up. The test will then progressively increase in speed and gradient every 2 minutes until the participant is no longer able to continue the exercise (volitional exhaustion). Throughout this procedure each participant will be required to wear a face mask connected to a gas analyser, allowing breath-by-breath oxygen consumption to be continuously measured Upon completion of the test, the gradient and the speed of the treadmill will be reduced and the participants will perform a cool down for 3-5 minutes. | Pre and post intervention (12 weeks) | |
Primary | Change in Flow Mediated Dilatation (FMD) | Brachial artery FMD, as a non-invasive measure of endothelial nitric oxide function, will be assessed using high resolution Duplex vascular ultrasonography in accordance with published guidelines. | Pre and post intervention (12 weeks) | |
Secondary | Change in sublingual glyceryl trinitrate (GTN) induced dilatation | Sublingual Glyceryl Trinitrate (GTN): Following 10 minutes of supine rest, endothelium independent vasodilator function will be assessed simultaneously in the brachial and carotid artery. A 1-minute baseline recording of the brachial and carotid artery will be acquired on the same high-resolution ultrasound device before sublingual administration of glyceryl trinitrate (GTN; 400µg). GTN is a nitric oxide donor that will cause the arteries to vasodilate allowing a short-lived increase in blood flow. Both the brachial and carotid artery will be imaged for 10-minutes following the administration of GTN and peak diameter and blood flow will be recorded. GTN has been used for many decades in clinical and research work in this and other populations. | Pre and post intervention (12 weeks) | |
Secondary | Change in cold pressor induced dilatation | Cold Pressor Test: Following 15 minutes supine rest, carotid artery reactivity (CAR) to a sympathetic stimulation produced by the cold pressor test (CPT) will be measured. The same ultrasound probe will be repositioned onto the participant's neck and an image of the carotid artery will be recorded continuously for one minute before and then during 3 minutes of hand-to-wrist submersion in ice cold water (4 °C). After the 3 minute CPT, the participant will then remove their hand from the cold water and we will continue to image the carotid artery for an additional 3 minutes. Peak carotid artery diameter and blood flow velocity, and the time taken to reach these peaks during the CPT will be recorded. This procedure has been shown to be reliable and well tolerated in this population. | Pre and post intervention (12 weeks) | |
Secondary | Change in arterial stiffness | Carotid - femoral pulse wave velocity (CF-PWV) will be recorded following 15 minutes of supine rest via applanation tonometry. This measure is the accepted gold standard for non-invasive measurement of arterial stiffness and has been previously validated in this population. The arterial wave form will be recorded at the wrist, neck and groin using a high fidelity micromanometer tipped probe and gated to a 3-lead ECG for measurement of PWV via the SphygmoCor system (SphygmoCor, AtCor-Medical, Sydney, Australia). Pulse wave analysis (PWA) will also be used to measure aortic pressure using the SphygmoCor system. | Pre and post intervention (12 weeks) | |
Secondary | Change in ultrasound assessment of cerebrovascular function- Assessment of cerebrovascular reactivity | Participants will then return to the assessment bed and lay supine for 10 minutes. Following this, participants will perform a carbon dioxide breathing challenge. The protocol will involve the participants breathing a fixed gas mixture of otherwise normal atmospheric air that has a mildly elevated fractional concentration of carbon dioxide (6%). This technique has been routinely used within this population and published guidelines will be followed. Normal atmospheric oxygen content is maintained throughout. Participants will be fitted with a face mask covering their nose and mouth with a one-way valve to prevent rebreathing. An elevation in the fractional concentration of carbon dioxide will be applied for 6 minutes and cerebrovascular blood flow will be measured continuously throughout this protocol, as per published guidelines. This procedure enables the maximal dilation capacity of the cerebrovascular blood vessels to be assessed. | Pre and post intervention (12 weeks) | |
Secondary | Change in ultrasound assessment of cerebrovascular function -Dynamic cerebral autoregulation | Participants will perform a cyclical squat-to-stand protocol. Participants will start in a standing position and then adopt a squat position where the back of their legs are at a ~90? angle. This manoeuvre will be repeated and performed at frequency of 10 seconds of squatting, followed by 10 seconds of standing. The duration of the protocol will be 5 minutes. This technique has been used routinely in older populations and is well tolerated and validated. | Pre and post intervention (12 weeks) | |
Secondary | Change in ultrasound assessment of cerebrovascular function - Cerebrovascular reactivity to an acute bout of exercise | After 15 minutes of rest, participants will perform a 10 - 15 minute bout of moderate intensity exercise at 50% predicted heart rate reserve (HRR) on a cycle ergometer. | Pre and post intervention (12 weeks) | |
Secondary | Change in ultrasound assessment of cerebrovascular function - Assessment of neurovascular coupling | Localised changes in cerebrovascular blood flow will be assessed during neuronal activation. The occipital lobe will be activated using a visual stimulus of a flashing checkerboard and participant's will then perform a series of short and repetitive sensory tasks. Sensory stimulation tasks will involve a simple cyclical eye opening and closing protocol, reading a short passage from an non-emotive text book and performing a simple visualisation cognitive task. This technique is frequently used in older populations and a standardised and validated protocol will be adopted. | Pre and post intervention (12 weeks) | |
Secondary | Change in Cognitive Function Assessment | Cognitive Function Assessment: Participants will be asked to complete the Montreal Cognitive Assessment. This paper-based assessment has been validated in this population and examines short term memory, visuospatial abilities, executive functions, attention, concentration and working memory, language and orientation to time and place. The test is scored based on a minimum score of 0 to a maximum score of 30, where a score of >26 is regarded as 'normal cognitive function' and a score of <26 indicative of mild cognitive impairment. | Pre and post intervention (12 weeks) | |
Secondary | Change in blood lipid profile | A 30ml blood sample will be taken from a vein in the arm and analysed for markers of cardiovascular risk. Blood samples will be analysed using the Randox Dayton+ analyser with standard proprietary reagents for total cholesterol, high-density lipoprotein, triglyceride (all lipid measures in mmol). Low-density lipoprotein will then be calculated using according to the Friedwald formula (mmol). | Pre and post intervention (12 weeks) | |
Secondary | Change in blood glucose and insulin profile | A 30ml blood sample will be taken from a vein in the arm and analysed for markers of cardiovascular risk. Blood samples will be analysed using the Randox Dayton+ analyser with standard proprietary reagents for glucose and insulin assayed using commercially available radioimmunoassay (both measures in mmol). Using fasting glucose and insulin concentrations, we then will calculate steady-state beta cell function and insulin resistance via the homeostasis model assessment. | Pre and post intervention (12 weeks) | |
Secondary | Changes in blood pro-inflammatory cytokines | A 30ml blood sample will be taken from a vein in the arm and simultaneously analysed for pro-inflammatory cytokines; Interleukin-1a, Interleukin-1ß, Interleukin-6, Interleukin-8, Interleukin-10 Interferon-? and Tumour Necrosis Factor-a,(all measured in pg/ml) using high sensitivity multiplex enzyme-linked immunosorbent assays (ELISA). | Pre and post intervention (12 weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|